Albireo Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- Marvell Technology shares rise on analyst support
Albireo Pharma (ALBO) Misses Q1 EPS by 7c, Revenues Miss
May 9, 2019 7:40 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($1.39), $0.07 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $970 thousand.
For Albireo, 2019 is focused on advancing toward potential approval and launch of odevixibat in its first... More



